Clinical Trial

Dexmedetomidine to Reduce the Incidence of POCD After Open Cardiac Surgery

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 24, 2024 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investigators propose to investigate the role of Dexmedetomidine (DEX) in preventing long-term POCD after cardiac surgery and enhancing early postoperative recovery. It is anticipated that DEX will be the first effective preventative therapy for POCD, improve patient outcomes, and reduce length of stay and healthcare costs.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2018-03-26; most recent amendment 2024-12-19.
Status change: Recruiting → Active, Not Recruiting 2020-08-05
Status change: Not Yet Recruiting → Recruiting 2018-08-09
Trial Details
NCT Number NCT03480061
Lead Sponsor Sunnybrook Health Sciences Centre
Conditions Delirium, Postoperative Cognitive Dysfunction, Dexmedetomidine, Cognitive Impairment, Depression
Enrollment 90 participants
Start Date 2018-08-09
Primary Completion 2026-07 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-12-24